Swiss drug company Roche has entered into a definite merger agreement to acquire Anadys Pharmaceuticals for $230 million.
The company said on Monday that it will buy Anadys, a developer of oral and small molecule therapeutics for the treatment of hepatitis C (HCV), for $3.70 a share in an all-cash transaction.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Setrobuvir (ANA598), Anadys’ most advanced drug candidate, is currently being evaluated by Anadys in a Phase II study in combination with Roche’s pegylated interferon (Pegasys) and ribavirin (Copegus).
Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development, said: "This acquisition augments our already strong HCV portfolio. Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon."
Anadys is also developing ANA773, an oral, small-molecule inducer of innate immunity in Phase I trials that may prove useful for treating HCV and cancer.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
